Literature DB >> 2210669

Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children.

P I Lee1, M H Chang, C Y Lee, H Y Hsu, J S Chen, P J Chen, D S Chen.   

Abstract

During a follow-up period of 3.2 +/- 1.6 (1 to 8.6) yr, 1,087 serum specimens from 230 HBsAg carrier children were tested for hepatitis B virus markers. Dividing the serum specimens into four groups according to the status of HBeAg and hepatitis B virus DNA, the frequency of abnormally elevated ALT levels in serum was in the following order: HBeAg(+)/hepatitis B virus DNA(-) serum (60%), HBeAg(-)/hepatitis B virus DNA(+) serum (53%), HBeAg(+)/hepatitis B virus DNA(+) serum (41%), HBeAg(-)/hepatitis B virus DNA(-) serum (11%). Analysis of the data before HBeAg clearance showed that both a high serum ALT level and a low serum hepatitis B virus DNA level correlated with an imminent clearance of HBeAg. Approximately two thirds of children with serum ALT levels higher than 100 IU/L cleared HBeAg within the following year. Clearance of HBeAg occurred within the following year in 65% (13 of 20) of cases with serum hepatitis B virus DNA level less than or equal to 1,000 pg/ml, in contrast to 19% (30 of 157) of those with serum hepatitis B virus DNA level greater than 1,000 pg/ml. Among 53 children who lost HBeAg and hepatitis B virus DNA during follow-up, only nine cases did not have an identified period of abnormal serum ALT levels. For the remaining 44 children, abnormal serum ALT levels fell to normal with clearance of both HBeAg and hepatitis B virus DNA in 33 children but remained elevated in the remaining 11 cases after seroconversion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210669     DOI: 10.1002/hep.1840120406

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

Authors:  S L Tsai; P J Chen; M Y Lai; P M Yang; J L Sung; J H Huang; L H Hwang; T H Chang; D S Chen
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

Review 2.  Chronic viral hepatitis.

Authors:  M H Chang
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

Review 3.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 4.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  Hepatitis B vaccination in preterm infants.

Authors:  F Y Huang; P I Lee; C Y Lee; L M Huang; L Y Chang; S C Liu
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

6.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

7.  The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers.

Authors:  K Fujiwara; O Yokosuka; T Ehata; W L Chuang; F Imazeki; H Saisho; M Omata
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

8.  Interferon alfa-2b therapy in children with chronic hepatitis B.

Authors:  E M Sokal; S Wirth; P Goyens; A Depreterre; C Cornu
Journal:  Gut       Date:  1993       Impact factor: 23.059

9.  Clinical significance of low or negative titer of antibody to hepatitis B core antigen during the course of chronic hepatitis B virus infection in adolescents.

Authors:  K Matsuura; K Tobe; Y Iwasaki; H Ikeda; K Takahashi; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1993-02

10.  TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence.

Authors:  Cheng Sun; Binqing Fu; Yufeng Gao; Xiaofeng Liao; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  PLoS Pathog       Date:  2012-03-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.